RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

Jul 22, 2015, 11:40 ET from RegeneRx Biopharmaceuticals, Inc.

ROCKVILLE, Md., July 22, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Australian government has issued a Notice of Acceptance for a patent for a key peptide fragment of Thymosin beta 4 (TB4). The patent claims are directed to the composition of matter and methods of use, including inhibiting tissue damage caused by ultraviolet radiation and promoting neurite outgrowth and neuron survival, among others.  The patent expiry is expected to be 2029.

"This is a very biologically active peptide fragment of TB4 as indicated in a number of animal models that we believe has properties that could be useful in both medical, as well as cosmeceutical, product candidates," stated Dr. Allan L. Goldstein, Emeritus Chairman of the Department of Biochemistry and Molecular Medicine at the George Washington University School of Medicine and RegeneRx's chief scientific advisor.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products.  RGN-259, the Company's TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx's clinical development efforts in the U.S through its joint venture, ReGenTree.  RegeneRx was recently allowed by the FDA to move into Phase 3 clinical trials with RGN-259 for the treatment of patients with NK.  RGN-352, the Company's TB4-based injectable drug candidate, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar injuries. For additional information about RegeneRx please visit www.regenerx.com.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company, including this most recent patent acceptance for a peptide fragment of Thymosin beta 4 (TB4), in Australia or any other country will result in approved products or future value.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

SOURCE RegeneRx Biopharmaceuticals, Inc.



RELATED LINKS

http://www.regenerx.com